Get the Stockscreener App
122.95
1.75%
2.11
After Hours:
122.95
Illumina Inc stock is traded at $122.95, with a volume of 1.20M.
It is up +1.75% in the last 24 hours and up +2.38% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$120.84
Open:
$120.35
24h Volume:
1.20M
Relative Volume:
0.60
Market Cap:
$18.80B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
22.50
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
+1.19%
1M Performance:
+2.38%
6M Performance:
+19.33%
1Y Performance:
+44.38%
1-Day Range:
$119.61
$123.85
1-Week Range:
$115.31
$123.85
52-Week Range:
$68.70
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
122.95 | 18.24B | 4.34B | 850.00M | 921.00M | 5.4635 |
|
TMO
Thermo Fisher Scientific Inc
|
464.69 | 174.60B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
191.50 | 135.34B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
577.12 | 46.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.50 | 31.60B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
295.05 | 28.45B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina and Labcorp expand cancer testing collaboration By Investing.com - Investing.com India
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina, Labcorp Expand Collaboration to Advance Precision Oncology Testing - marketscreener.com
Illumina and Labcorp expand cancer testing collaboration - Investing.com
Synthetic Biology Market to Reach US$ 67.47 Billion by 2033 | - openPR.com
Labcorp–Illumina cancer pact targets wider access to genomic tests - Stock Titan
Investment Report: Is Illumina Inc stock a good dividend stockPortfolio Update Report & Weekly Breakout Watchlists - baoquankhu1.vn
U.S. Bioinformatics Market Is Booming Rapidly with Strong - openPR.com
Life Sciences Tools & Services Stocks Q4 Earnings: Illumina (NASDAQ:ILMN) Firing on All Cylinders - TradingView
Illumina Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Gotham Asset Management LLC Purchases 144,475 Shares of Illumina, Inc. $ILMN - MarketBeat
How Illumina’s Genomics Insurance Push And Multiomic Alliance Expansion At Illumina (ILMN) Has Changed Its Investment Story - simplywall.st
Illumina Adds Activist to Board, Names Former FDA Chief as Chair - MSN
Illumina Stock: Here’s Why Numbers Suggest a 63% Upside - TIKR.com
Illumina partners with Veritas to offer genome sequencing via insurers - Investing.com
DNA screening through health plans: Illumina’s push for preventive genomics - Stock Titan
Illumina, Inc. $ILMN Shares Sold by Ion Asset Management Ltd. - MarketBeat
Bamco Inc. NY Sells 39,378 Shares of Illumina, Inc. $ILMN - National Today
Illumina, Inc. $ILMN Stake Lessened by Cannell & Spears LLC - MarketBeat
Illumina, Inc. $ILMN Shares Sold by Casdin Capital LLC - MarketBeat
Illumina Inc. Stock (ISIN: US4523271090) Gains on Institutional Buying and Genomic Alliance Momentum - AD HOC NEWS
Illumina (ILMN) Valuation Check As Genomic Discovery Alliance Expansion Draws Fresh Investor Interest - simplywall.st
Is It Time To Reconsider Illumina (ILMN) After Prolonged Share Price Weakness? - Yahoo Finance
Spyglass Capital Management LLC Decreases Holdings in Illumina, Inc. $ILMN - MarketBeat
Quinn Opportunity Partners LLC Sells 62,423 Shares of Illumina, Inc. $ILMN - MarketBeat
Perbak Capital Partners LLP Purchases 14,315 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina Alliance Expansion With Regeneron Fuels Multiomic Data Opportunity - simplywall.st
Illumina Inc.: Why This DNA Giant Just Got Way More Interesting for You - AD HOC NEWS
Swiss National Bank Reduces Illumina Holdings - National Today
Russell Investments Group Ltd. Boosts Stake in Illumina, Inc. $ILMN - MarketBeat
Swiss National Bank Has $43.34 Million Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Schroder Investment Management Group Sells Illumina Shares - National Today
Rep. Gilbert Ray Cisneros, Jr. Buys Illumina, Inc. (NASDAQ:ILMN) Stock - MarketBeat
Schroder Investment Management Group Sells 66,235 Shares of Illumina, Inc. $ILMN - MarketBeat
First Trust Advisors LP Sells 89,600 Shares of Illumina, Inc. $ILMN - MarketBeat
Korea Investment CORP Purchases 60,500 Shares of Illumina, Inc. $ILMN - MarketBeat
ILMN SEC FilingsIllumina Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Returns Recap: Does Illumina Inc have consistent dividend growth2026 Action & Long-Term Investment Growth Plans - baoquankhu1.vn
Illumina's new connected multiomics platform set to boost its stock - MSN
Illumina partnership aims to speed rare disease diagnosis in Florida - AADC News
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally? - The Globe and Mail
Bioinformatics Market to Reach US$ 29.1 Billion by 2031 Growing - openPR.com
Capital International Inc. CA Boosts Stake in Illumina - National Today
Capital International Inc. CA Boosts Stock Holdings in Illumina, Inc. $ILMN - MarketBeat
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Inceptionr LLC Invests in Illumina, Inc. - National Today
Here’s Why Illumina Stock Could Continue Its 44% Recovery Into 2026 - TIKR.com
Capital World Investors Acquires 3,331,542 Shares of Illumina, Inc. $ILMN - MarketBeat
Capital International Sarl Buys 24,055 Shares of Illumina, Inc. $ILMN - MarketBeat
Illumina, Inc. $ILMN Stock Holdings Increased by Capital International Ltd. CA - MarketBeat
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):